

091-20204fa

For Internal Use Only
Sec File No. 9-RECEIVED

Submit 1 Original
and 9 Copies

| | |
|---|---------------|
| OMB APPROVAL | |
| OMB Number: | 3235-0504 |
| Expires: | July 31, 2016 |
| Estimated average burden hours per response: | 3.60 |

2016 JAN 19 AM 1:52
SEC / TM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

REC'D
2016 FEB -2 AM 4:54
SEC / TM

FORM 19b-4(e)

Information Required of a Self-Regulatory Organization Listing and Trading a New
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934

SEC

READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM

Mail Processing
Section

Part I

Initial Listing Report

FEB 02 2016

1. Name of Self-Regulatory Organization Listing New Derivative Securities Product:
EDGA Exchange, Inc.

Washington DC
404

2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):
See Attached.

3. Class of New Derivative Securities Product:
See Attached.

4. Name of Underlying Instrument:
See Attached.

5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:
See Attached.

6. Ticker Symbol(s) of New Derivative Securities Product:
See Attached.

7. Market or Markets Upon Which Securities Comprising Underlying Instrument
Trades: See Attached.

8. Settlement Methodology of New Derivative Securities Product:
Trades Locked in at Exchange and settled at NSCC.

9. Position Limits of New Derivative Securities Product (if applicable):
Not Applicable.



Part II

Execution

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form: Anders Franzon

Title: VP, Associate General Counsel

Telephone Number: 913-815-7154

Manual Signature of Official Responsible for Form:

Date: February 1, 2016

| | |
|---------------|---------------------------------|
| Act | Securities Exchange Act of 1934 |
| Section | 19b-4 |
| Rule | 19b-4(e) |
| Public | |
| Availability: | FEB 02 2016 |

ATTACHMENT TO FORM 19b-4(e)
 FOR NEW DERIVATIVE SECURITIES PRODUCTS ("NDSPs") TRADED ON EDGA EXCHANGE, INC.
 COMMENCING ON FEBRUARY 01, 2016

| <u>(6) Ticker Symbol</u> | <u>(2) Type of Issuer of NDSP</u> | <u>(3) Class of NDSP</u> | <u>(4) Name of Underlying Instrument</u> | <u>(7) Market(s) upon Which Securities Comprising Underlying Instrument Trades</u> | <u>(5) Broad or Narrow</u> |
|--------------------------|-----------------------------------|--------------------------|---|--|----------------------------|
| BBH | Trust | Investment Company Units | Market Vectors® US Listed Biotech 25 Index | U.S. | Broad |
| PPH | Trust | Investment Company Units | Market Vectors® US Listed Pharmaceutical 25 Index | U.S. | Broad |



RECEIVED

JAN 19 11:52

SEC/AM

SEC
Mail Processing
Section

FEB 02 2016

Washington DC
404

February 1, 2016:

Ms. Gail Jackson
Mail Stop 6628
Securities and Exchange Commission
100 F. Street, N.E.
Washington, DC 20549

RE: Form 19b-4(e) - EDGA Exchange, Inc.

Ms. Jackson,

On behalf of EDGA Exchange, Inc., enclosed please find one (1) executed Form 19b-4(e) and 9 copies. The enclosed Form 19b-4(e) contains information regarding two (2) derivative securities products that commenced trading on EDGA Exchange on February 1, 2016. Please contact me or Tami Schademann (913.815.7113) if you have any questions in connection with this matter.

Sincerely,

Anders Franzon
SVP, Associate General Counsel
913.815.7154

| | |
|----------------------|---------------------------------|
| Act | Securities Exchange Act of 1934 |
| Section | 19b-4 |
| Rule | 19b-4(e) |
| Public Availability: | FEB 02 2016 |